반응식
[CH3:1][C:2]1[C:10]2[C:5](=[CH:6][CH:7]=[C:8]([C:11]([N:13]3[CH2:18][CH2:17][C:16]4([CH2:27][C:26](=[O:28])[C:25]5[C:20](=[CH:21][CH:22]=[C:23]([C:29]6[CH:30]=[N:31][N:32]([CH3:34])[CH:33]=6)[CH:24]=5)[O:19]4)[CH2:15][CH2:14]3)=[O:12])[CH:9]=2)[NH:4][N:3]=1.[CH3:35][O:36][C:37]([C:39]1[CH:40]=[C:41](B(O)O)[CH:42]=[CH:43][CH:44]=1)=[O:38].COC(C1C=CC(B(O)O)=CC=1)=O>>[CH3:1][C:2]1[C:10]2[C:5](=[CH:6][CH:7]=[C:8]([C:11]([N:13]3[CH2:14][CH2:15][C:16]4([CH2:27][C:26](=[O:28])[C:25]5[C:20](=[CH:21][CH:22]=[C:23]([C:29]6[CH:30]=[N:31][N:32]([CH3:34])[CH:33]=6)[CH:24]=5)[O:19]4)[CH2:17][CH2:18]3)=[O:12])[CH:9]=2)[N:4]([C:43]2[CH:44]=[C:39]([CH:40]=[CH:41][CH:42]=2)[C:37]([O:36][CH3:35])=[O:38])[N:3]=1참가 물질
4
반응물 3
생성물 1
실험 절차
The intended compound was produced according to the procedure described in Example 28-2 but using 1′-[(3-methyl-1H-indazol-5-yl)carbonyl]-6-(1-methyl-1H-pyrazol-4-yl)spiro[chroman-2,4′-piperidin]-4-one and [3-(methoxycarbonyl)phenyl]boronic acid in place of 1′-[(3-methyl-1H-indazol-6-yl)carbonyl]-6-(1-methyl-1H-pyrazol-4-yl)spiro[chroman-2,4′-piperidin]-4-one and [4-(methoxycarbonyl)phenyl]boronic acid.
후처리
- customThe intended compound was produced
출처 및 근거
- ORD 기록
- ord-87e6f9a9af334c1caa8640553460e833
- 출처 데이터셋
- uspto-grants-2013_09
- 특허 번호
- US08524730B2
연결된 노트
불러오는 중…